Apr 29, 2019
EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014
Apr 29, 2019
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer
Mar 28, 2019
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Mar 28, 2019
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
Mar 18, 2019
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Approved for Australian Women(1)
Feb 28, 2019
Halozyme Announces FDA Approval Of Herceptin Hylecta(TM)
Feb 17, 2019
New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program
Feb 13, 2019
Cancer Research Pioneer Dr. H. Michael Shepard Joins Anpac Bio Technical Advisory Board
Feb 07, 2019
Paramount Developments Crucial for Advancing Clinical Trials Targeting Cancer Treatments
Jan 14, 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Dec 17, 2018
NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab)
Dec 08, 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 05, 2018
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Nov 27, 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
Nov 19, 2018
Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Nov 14, 2018
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients
Nov 01, 2018
Global Biosimilars Market Report 2018-2025 - Patent Expiration of Biologics to Boost the Biosimilars Market
Oct 23, 2018
NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
Oct 22, 2018
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
Oct 21, 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress